Refractory Mantle Cell Lymphoma
Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis
... relapsed/refractory mantle cell lymphoma ...simplified Mantle Cell Lymphoma International Prognostic Index (MIPI) scores (ie, secondary MIPI) based on parameters at the ...
7
Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
... with mantle cell lymphoma (MCL) have a poor prognosis; consequently, new therapeutic approaches, such as rapamycin and its derivates, mammalian target of rapamycin (mTOR) inhibitors, are ...MCL ...
9
<p>Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date</p>
... Three BTK inhibitors are currently approved by the US Food and Drug Administration (FDA) in relapsed/refrac- tory MCL: ibrutinib, acalabrutinib, and zanubrutinib. These 3 BTK inhibitors inactivate BTK by irreversibly ...
9
Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
... The treatment of MCL has evolved greatly in the last decade. The application of targeted therapies in the second-line setting has expanded treatment options for patients with relapsed or refractory disease. The ...
12
NF-κB signaling and its relevance to the treatment of mantle cell lymphoma
... Mantle cell lymphoma is an aggressive subtype of non-Hodgkin B cell lymphoma that is characterized by a poor prognosis determined by Ki67 and Mantle Cell International ...
11
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
... Results: Of 58 enrolled patients (median age, 71 years; range, 50 – 89), 13 received lenalidomide monotherapy, 11 lenalidomide plus rituximab, and 34 lenalidomide plus other treatment. Most patients (88%) had received ≥ ...
8
Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
... cycles, twice weekly (days 1, 4, 8, and 11) for the first 2 weeks followed by a 10-day rest period in each cycle. Two additional cycles of VR-CAP were recommended for patients who first demonstrated a response at cycle ...
12
Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation
... Abstract: Mantle cell lymphoma (MCL) is a type of non-Hodgkins lymphoma (NHL) associated with poor progression-free and overall ...stem cell transplant (autoSCT) have shown promise in ...
10
Gene mutations and actionable genetic lesions in mantle cell lymphoma
... We reviewed literature published in the last 10 years that describe recurrent gene mutations in mantle cell lymphoma and their role in the treatment bottleneck of drug resistance. We identified from ...
11
Spontaneous regression of mantle cell lymphoma: a report of four cases
... chemotherapy- refractory B-cell malignancies were successfully treated with anti-CD19 CAR T ...MCL cell surface [25], and MCL cells are sensitive to the CTL019 (cytotoxic T lymphocytes targeting CD19 ...
6
Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents
... In addition to inhibiting the ubiquitin-proteasome complex, proteasome inhibitors induce the death response in transformed cells by inhibition of NF-κB-mediated anti-apoptotic response, upregulation of pro-apoptotic ...
40
Mantle Cell Lymphoma: Effectiveness of Maintenance Ibrutinib – Case Report
... The results of the LYMA study also turned out to be very interesting. They included younger, untreated MCL patients (18-65 years old). In the induction treatment, the R-DHAP system was administered (in the absence of a ...
9
Novel targeted therapies for mantle cell lymphoma
... and frequent need for dose reductions, a phase II study of 25 mg weekly of temsirolimus was performed. The ORR was 41% with a median time to progression of 6 months. The authors concluded that the lower dose retained ...
9
A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia
... for mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), small molecules, such as ibrutinib, are beginning to play a significant role, particularly in patients with multiply relapsed or ...
12
Mantle cell lymphoma and its management: where are we now?
... Mantle cell lymphoma is a relatively new recognized hematological malignant disease, comprising of ...disease. Mantle cell international prognostic index (MIPI), ki-67 proliferation ...
9
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
... on lymphoma cells of case 1, case 3, case 5, case 6, and case 7 is 50, 20, 30, 70, and 30% ...NK cell lymphomas, EBV DNA was an important prognostic element for disease-free sur- vival (DFS) and overall ...
8
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
... T-cell lymphoma (PTCL, ...aggressive lymphoma requires not only considerations regarding efficacy but also careful evaluation of toxicities as well as overall clinical ...
10
A comparison between protein profiles of B cell subpopulations and mantle cell lymphoma cells
... MCL cell lines Granta 519, SP53 and NCEB1 have earlier been shown to cluster closely to primary MCL sam- ples ...other cell lines did not cluster together with the B cell subpopulations they were ...
8
Synchronous Adenocarcinoma and Mantle Cell Lymphoma of the Stomach
... tional Lymphoma Study Group (ILSG) published 'Revised European American Classification of Lymphoid Neoplasm' integrating all the mor- phologic, immunologic, genetic, and molecular biologic ...
5
Pathologic Rupture of the Spleen in Mantle-Cell-Type Non-Hodgkin’s Lymphoma
... Mantle cell lymphoma (MCL) accounts for less than 10 percent of all non-Hodgkin’s lymphoma ...with lymphoma; however only 5 cases have been reported in patients with ...
5